# A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

> **NCT01711814** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 611 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** peficitinib

## Key facts

- **NCT ID:** NCT01711814
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-26
- **Primary completion:** 2016-03-25
- **Final completion:** 2016-03-25
- **Target enrollment:** 611 (ACTUAL)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01711814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01711814, "A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01711814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*